Elicio Therapeutics (ELTX) Accumulated Expenses (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Accumulated Expenses data on file, last reported at $5.9 million in Q1 2026.

• Quarterly Accumulated Expenses rose 2.51% year-over-year to $5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.9 million (up 2.51% YoY) and the FY2025 annual result came in at $6.4 million, down 23.62% from the prior year.
• Accumulated Expenses retreated to $5.9 million in Q1 2026, from $6.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $8.4 million in Q4 2024 to a low of $1.1 million in Q1 2023.
• A 5-year average of $4.6 million and a median of $4.9 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses plunged 78.96% — and 2024, when it surged 201.36%.
• Tracing ELTX's Accumulated Expenses over 5 years: stood at $1.9 million in 2022, then surged by 94.16% to $3.8 million in 2023, then jumped by 123.98% to $8.4 million in 2024, then decreased by 23.62% to $6.4 million in 2025, then retreated by 7.97% to $5.9 million in 2026.
• The last three Accumulated Expenses figures came in at $5.9 million (Q1 2026), $6.4 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.